D'Alonzo G E, Smolensky M H, Feldman S, Gianotti L A, Emerson M B, Staudinger H, Steinijans V W
Pulmonary Division, University of Texas Health Science Center, Houston.
Am Rev Respir Dis. 1990 Jul;142(1):84-90. doi: 10.1164/ajrccm/142.1.84.
Many patients with asthma experience a worsening of symptoms at night and in the early morning, resulting in sleep disruption and possibly altered daily performance. A bronchodilator agent that exerts its maximal effect overnight to control nocturnal symptoms, without a worsening of the disease during the daytime, should improve the treatment of asthma. This investigation examined the efficacy and kinetics of a new chronotherapeutically optimized, sustained-release theophylline formulation administered once daily (OD) in the evening at 8:00 P.M. in comparison with a conventional sustained-release theophylline administered twice daily (TD) at 8:00 A.M. and at 8:00 P.M. in the same dose. After a theophylline clearance study to substantiate normal or slow metabolism of the drug, a dose-titration period, and a 24-h baseline spirometric study of patients not receiving any medication, participants were randomized to 7-day treatment phases with either OD or TD. Each outpatient segment of 6 days of OD and TD was followed by a 24-h inpatient study on Day 7 when serum drug level and spirometric (PEF, FEV1, and FEF25-75) parameters were obtained every 2 h. The conventional TD treatment was associated with a constant serum theophylline level over the 24 h. In contrast, the OD treatment was associated with larger peak-to-trough drug level fluctuation, with higher levels produced overnight and lower ones in the evening at the end of the dosing interval. Compared with the baseline references, both OD and TD significantly improved airflow over the entire 24 h and to a comparable extent. However, between 2:00 and 6:00 A.M., PEF and FEV1 were significantly greater with OD than with TD. The improvement in PEF and FEV1 at this time, because of OD, was correlated with the serum theophylline level. This was not the case for TD. The improvement in airflow over baseline values between 2:00 and 6:00 P.M. was not correlated with theophylline level with either treatment regime. Overall, the chronotherapeutically conceptualized OD treatment administered in the evening resulted in better airflow levels overnight than did the TD regime without loss of airflow in the afternoon.
许多哮喘患者在夜间和清晨会出现症状加重的情况,导致睡眠中断,并可能影响日常活动表现。一种能在夜间发挥最大作用以控制夜间症状,且不会在白天使病情恶化的支气管扩张剂,应能改善哮喘的治疗效果。本研究考察了一种新的经时辰治疗优化的缓释茶碱制剂的疗效和动力学,该制剂于晚上8点每日一次(OD)给药,并与相同剂量的传统缓释茶碱制剂每日两次(TD)于上午8点和晚上8点给药进行比较。在进行茶碱清除率研究以证实药物代谢正常或缓慢、剂量滴定期以及对未接受任何药物治疗的患者进行24小时基线肺量计研究后,参与者被随机分为接受OD或TD治疗的7天治疗阶段。OD和TD各6天的门诊治疗阶段之后,在第7天进行24小时住院研究,每2小时测定一次血清药物水平和肺量计参数(呼气峰流速(PEF)、第1秒用力呼气容积(FEV1)和用力呼气中期流速(FEF25 - 75))。传统的TD治疗在24小时内血清茶碱水平保持恒定。相比之下,OD治疗的血药浓度峰谷波动较大,给药间隔结束时夜间血药浓度较高,晚上较低。与基线参考值相比,OD和TD在整个24小时内均显著改善了气流,且改善程度相当。然而,在凌晨2点至6点之间,OD组的PEF和FEV1显著高于TD组。此时,由于OD治疗导致的PEF和FEV1改善与血清茶碱水平相关。TD治疗则并非如此。两种治疗方案在下午2点至6点之间气流较基线值的改善均与茶碱水平无关。总体而言,晚上进行的经时辰治疗概念化的OD治疗在夜间产生的气流水平优于TD治疗方案,且下午气流水平未降低。